Accelerating pharmaceutical structure guided drug design: a successful model.
The impact and value of structure based drug design to pharmaceutical discovery across the industry are now undeniable, with many break through therapies on the market that are structure based in nature. Enabling the structural research is the Industrial Macromolecular Crystallography Association Collaborative Access Team (IMCA CAT) formed over 25 years ago as a world class research facility at the synchrotron at Argonne National Laboratory. What makes IMCA CAT unique is the strategy of the founding consortium to comprehensively provide for the evolving needs of industry in one facility. This includes year round high quality data, capabilities that match target portfolios, throughput and capacity that are never limiting, and unfailing security. Here, we illuminate the unique capabilities offered by IMCA CAT and instruct how all industrial organizations can access this facility.
Drug discovery today